ANTURANE Drug Patent Profile
When do Anturane patents expire, and when can generic versions of Anturane launch?
Anturane is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in ANTURANE is sulfinpyrazone. There is one drug master file entry for this compound. Additional details are available on the sulfinpyrazone profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ANTURANE?
- What are the global sales for ANTURANE?
- What is Average Wholesale Price for ANTURANE?
Summary for ANTURANE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 80 |
| DailyMed Link: | ANTURANE at DailyMed |
US Patents and Regulatory Information for ANTURANE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | ANTURANE | sulfinpyrazone | CAPSULE;ORAL | 011556-004 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Novartis | ANTURANE | sulfinpyrazone | TABLET;ORAL | 011556-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
